Nurix Therapeutics Inc. NRIX, set terms for its initial public offering on Thursday, with plans to offer 11 million shares priced at $17 to $18 each. The company has applied to list on Nasdaq, under the ticker “NRIX.” JPMorgan, Piper Sandler, Stifel and Needham & Co. are underwriting the deal. Proceeds will be used to fund clinical research and R&D, as well as for working capital and general corporate purposes. “We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders,” the company says in its prospectus.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.